Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Merkel

Rheumatology Radnor, PA Medical Doctor

NPI 1437136173 CMS profile 200458

250 King Of Prussia, Radnor, PA 19087

Open in the dashboard

General payments

$479,144

232 records reported · program years 2019–2025

Research payments

$10,393

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,867,067 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Peter Merkel of Radnor, PA is reported in the CMS Open Payments database as having received $479,144 across 232 general payments and $10,393 in research payments paid to them. Separately, studies naming them as principal investigator received $5,867,067 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $71,402 36
2025 Research $17 1
2024 General $102,107 42
2024 Research $3,579 2
2023 General $121,518 50
2023 Research $1,950 1
2022 General $62,828 31
2021 General $11,692 7
2020 General $32,781 10
2020 Research $4,847 1
2019 General $76,817 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Merkel
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Peter Merkel were reported at $71,402. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Peter Merkel Rheumatology median Middle half National median
2019 $76,817 $744 $153–$2,687 $163
2020 $32,781 $462 $98–$2,027 $114
2021 $11,692 $531 $101–$2,153 $132
2022 $62,828 $627 $125–$2,303 $149
2023 $121,518 $741 $145–$2,524 $160
2024 $102,107 $830 $166–$2,660 $164
2025 $71,402 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca UK Limited $120,943 36 payments
  2. NS Pharma, Inc. $96,717 15 payments
  3. AstraZeneca Pharmaceuticals LP $37,700 13 payments
  4. Amgen Inc. $32,928 26 payments
  5. Alexion Pharmaceuticals, Inc. $29,608 27 payments
  6. Novartis Pharma AG $20,808 5 payments
  7. Celgene Corporation $20,059 8 payments
  8. E.R. Squibb & Sons, L.L.C. $18,293 20 payments
  9. CSL Behring $13,446 6 payments
  10. Otsuka Pharmaceutical Development & Commercialization, Inc. $12,988 9 payments
  11. Other $75,654 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $444,464 132 payments
  2. Travel and Lodging $19,050 38 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,645 6 payments
  4. Honoraria $6,465 2 payments
  5. Food and Beverage $2,466 53 payments
  6. Education $55 1 payment
Products named General payments · program years 2019–2025
  1. FASENRA Respiratory $83,581 25 payments
  2. VILTEPSO $48,042 9 payments
  3. FASENRA Respiratory $43,330 16 payments
  4. BLZ_BEOVU_OPHTHALMOLOGY $15,616 3 payments
  5. TAVNEOS Inflammation $14,936 18 payments
  6. Tavneos Not Applicable $13,800 5 payments
  7. OFEV $10,773 14 payments
  8. KEVZARA $7,635 3 payments
  9. ORENCIA $6,214 10 payments
  10. VYVGART $6,175 4 payments
  11. Other $31,335 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $4,847 1 payment
  2. Amgen Inc. $2,546 2 payments
  3. Argenx US, Inc. $1,950 1 payment
  4. AbbVie, Inc. $1,050 1 payment

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$7,832

Medicare's payments for the services billed

Medicare patients

59

Average age 72

Services billed

163

35 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 68%
High blood pressure 61%
Osteoporosis 46%
Ischemic heart disease 32%
Chronic kidney disease 29%
Depression 20%
Diabetes 19%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca UK Limited $10,195
  • AstraZeneca Pharmaceuticals LP $8,125
  • AstraZeneca AB $550
$18,870 — —
TAVNEOS
  • Amgen Inc. $5,896
$5,896 — —
KEVZARA
  • GENZYME CORPORATION $3,645
$3,645 — —
Actemra
  • Chugai Pharmaceutical Co., Ltd. $3,640
$3,640 — —
OFEV
  • Boehringer Ingelheim International GmbH $1,500
$1,500 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record